KNSAKiniksa Pharmaceuticals Ltd - Ordinary Shares - Class A
KNSA
Kiniksa Pharmaceuticals Ltd - Ordinary Shares - Class A2,477
Mkt Cap
$3.3BVolume
1.11M52W High
$49.1252W Low
$18.26PE Ratio
58.68KNSA Fundamentals
Price
$42.76Prev Close
$43.50Open
$43.5050D MA
$42.82Beta
0.73Avg. Volume
736,242.30EPS (Annual)
$0.75P/B
6.13Rev/Employee
$2.15M$1,179.00
Earnings Recap
• Reported GAAP EPS of $0.19 up 258.33% YoY • Reported revenue of $202.13M up 64.95% YoY • Kiniksa expects 2026 ARCALYST net product revenue to be between $900M and $920M. Kiniksa also anticipates its current operating plan will remain cash flow positive on an annual basis.
Bullish
Kiniksa achieved strong ARCALYST revenue growth and significant net income, improving its financial position. The company also advanced its KPL-387 and KPL-1161 pipeline assets.
Bearish
Kiniksa faces increased operating expenses driven by collaboration costs, while key pipeline data and trial initiations are scheduled for late 2026, and ARCALYST carries immune system-related risks.